AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 281 min read$ANIX

KUMAR AMIT purchased $19K of ANIX

KUMAR AMIT (Chief Executive Officer) purchased 7,000 shares of Anixa Biosciences Inc (ANIX) at $2.78 on 2026-09-24.

Original reporting
SEC EDGAR · KUMAR AMIT
Published Sep 28, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIX
Neutral
high confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXNeutralLow
01

Why it matters

The modest size suggests minimal price impact, but it adds to the insider activity record for ANIX.

02

Market read

Primary insider purchase, low materiality, limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could make the insider stake more relevant.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings provide transparent disclosure of insider trades. This filing reports a modest open‑market purchase by the CEO.

Company-level read

Ticker impact

$ANIXNeutralHigh confidence
Context

SEC Form 4 disclosed CEO Kumar Amit bought 7,000 shares at $2.78, increasing his stake to 672,000 shares.

Expected impact

likely slight upward pressure as market absorbs insider buying.

Evidence & confidence

The transaction is a primary filing, but the dollar amount ($19K) is trivial for a public company, limiting market impact.

Market effects

Sector

None significant for the biotech sector.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Company
    Anixa Biosciences Inc

    Biotech firm developing therapies for rare diseases.

  • Person
    Kumar Amit

    Chief Executive Officer of Anixa Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIX insider trading history →

Related articles

OCT 6
$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

investing.com2 min
OCT 5
$ANIXMed

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences reported that a patient in its Phase 1 trial for ovarian cancer CAR-T therapy showed stable disease 3 months post-treatment. No dose-limiting toxicities were observed. The trial, conducted at Moffitt Cancer Center, aims to assess safety and preliminary efficacy of lira-cel, a novel CAR-T therapy targeting FSHR. Multiple patients have survived over a year, with one exceeding two years.

prnewswire.com2 min
OCT 1
$ANIXMedAI 8/10

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

prnewswire.com2 min
SEP 11
$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

finanznachrichten.de2 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min